Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin GB0009895292
Ticker AZN
Company ASTRAZENECA
Currency $
Price
Aware Investor Index (AII) 65.2775
Recommendation STRONG BUY
P/E 10.75
ROE 29.38 %
Capitalization 52,567,830,000 $
Dividend Yield 6.75 %
P/S 2.61
AII Position 38
P/E Position 64
ROE Position 89
Capitalization Position 163
Dividend Yield Position 34
Sales 20,152,000,000 $
10-Year Average Earnings 4,888,800,000 $
Shares Outstanding 1,267,000,000
Equity 16,642,000,000 $
Dividend per Share 2.8 $
Industry Pharmaceutical
Country Great Britain
ASTRAZENECA Investor Relations Web Site http://www.astrazeneca.com/Investors







Sales:

YEAR MONTH AMOUNT
2017 12 20,152,000,000.00 $
2016 12 21,319,000,000.00 $
2015 12 23,641,000,000.00 $
2014 12 26,095,000,000.00 $
2013 12 25,711,000,000.00 $
2012 12 27,973,000,000.00 $
2011 12 33,591,000,000.00 $
2010 12 33,269,000,000.00 $
2009 12 32,804,000,000.00 $
2008 12 31,601,000,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 2,868,000,000.00 $
2016 12 3,406,000,000.00 $
2015 12 2,826,000,000.00 $
2014 12 -271,000,000.00 $
2013 12 2,458,000,000.00 $
2012 12 6,405,000,000.00 $
2011 12 9,470,000,000.00 $
2010 12 8,106,000,000.00 $
2009 12 7,490,000,000.00 $
2008 12 6,130,000,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 16,642,000,000.00 $
2016 12 16,669,000,000.00 $
2015 12 18,509,000,000.00 $
2014 12 19,646,000,000.00 $
2013 12 23,253,000,000.00 $
2012 12 23,952,000,000.00 $
2011 12 23,472,000,000.00 $
2010 12 23,410,000,000.00 $
2009 12 20,821,000,000.00 $
2008 12 16,060,000,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 1,267,000,000
2016 12 1,266,000,000
2015 12 1,265,000,000
2014 12 1,264,000,000
2013 12 1,254,000,000
2012 12 1,261,000,000
2011 12 1,367,000,000
2010 12 1,446,000,000
2009 12 1,450,000,000
2008 12 1,453,000,000

 












Bloomberg News for ASTRAZENECA:



Google News for ASTRAZENECA:

StreetInsider.com - 1 day ago
AstraZeneca (AZN) Agrees to Sell Perpetual US Rights for Synagis ...
AstraZeneca (AZN) Agrees to Sell Perpetual U.S. Rights for Synagis ... to Synagis® (palivizumab) in the US from AstraZeneca (NYSE: AZN) and ...
Investor's Business Daily
Shore Capital Reiterates Hold Rating for AstraZeneca (AZN)
AstraZeneca (LON:AZN)'s stock had its “hold” rating reissued by investment analysts at Shore Capital in a research report issued on Monday.
Endpoints News
AstraZeneca (AZN) Given “Sell” Rating at HSBC
A number of other equities research analysts also recently commented on AZN. Zacks Investment Research upgraded AstraZeneca from a sell ...
Nasdaq
AstraZeneca (AZN) Reports Positive Full Results from DECLARE ...
AstraZeneca (NYSE: AZN) today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for ...
Fairfield Current - 4 hours ago
AstraZeneca's (AZN) Q3 Earnings Beat, New Drugs Drive Sales
With its product sales growing after a long time, Pascal Soriot, AstraZeneca's chief executive officer, said this marks “the start of a period of ...
PressOracle
AstraZeneca Q3 revenues down 14%
AstraZeneca (AZN) Q3 results: Revenues: $5,340M (-14.3%); Product Sales: $5,266M (+7.9%); Externalisation Revenue: $74M (-94.5%).
BharataPress
AstraZeneca plc (NYSE:AZN) is Proving to be a Stalwart Player in ...
AstraZeneca plc (NYSE:AZN) recently announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) ...
Baseball Daily News
AstraZeneca (LON:AZN) Receives “Outperform” Rating from Credit ...
Credit Suisse Group reaffirmed their outperform rating on shares of AstraZeneca (LON:AZN) in a report published on Monday, October 29th.
Fairfield Current - 20 hours ago
AstraZeneca (AZN) Gets a Sell Rating from HSBC
According to The Fly, hSBC analyst Steve McGarry maintained a Sell rating on AstraZeneca (AZN – Research Report) today. The company's ...
Marea Informative (blog)
Tencent Profit Tops Views, Revenue In Line Amid China Gaming ...
AstraZeneca (AZN) stock jumped Tuesday after the U.K.-based pharma giant said it would sell the U.S. rights to an infant respiratory drug for ...


Back